HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbal Supplement Popularity Grows Despite State Officials' Doubts

This article was originally published in The Rose Sheet

Executive Summary

The popularity of botanical and herbal supplements increased to 39% of users in 2017 despite state litigators’ enforcement against ingredients in products and their push for DNA barcode testing, the Council for Responsible Nutrition finds in its annual survey.

You may also be interested in...



Men's Vitamin C And D Use Helps Drive Overall VMS Use In Latest CRN Survey

Trade group's annual survey shows 77% of US consumers use supplements. It found 12% more men than four years ago report taking vitamin C or D within the past 12 months.

Independent Pharmacies Stock Growth Opportunities In Health, Wellness And Beauty Aisles

Vitamin and supplement marketers that work closely with independent pharmacies may rise above the fray in the retail space, suggests a Hamacher Resource Group analyst. Though VMS leads other categories in pharmacy chain, it is second in independent pharmacies due to shelf space constraints.

State AGs Out Of Their Bailiwick Testing Supplement Ingredient Identities

State AGs can determine whether a supplement label makes an unsubstantiated claim, their previous litigation target, but they aren't qualified to test ingredient identity, says Doreen Manchester in a FDLI presentation on state agencies' enforcement.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel